Lung Cancer Clinical Roundup

News Articles

(IDIBELL [Spain]) Oct 7, 2020 - A study has evaluated the efficacy and safety of the combination of 3 cycles of chemotherapy with immunotherapy (nivolumab) before surgery, in 51 patients with locally advanced lung cancer, followed by one year of treatment with immunotherapy.
(BMS) Oct 7, 2020 - Bristol Myers Squibb today announced that the Phase 3 CheckMate -816 trial met a primary endpoint of pathologic complete response (pCR) in resectable non-small cell lung cancer (NSCLC). In the trial, significantly more patients treated with Opdivo (nivolumab) plus chemotherapy before surgery showed no evidence of...
(Docwirenews) Oct 5, 2020 - The turn-around time for liquid biopsy is considerably faster than a tissue-based test, according to the findings of a pilot test presented today at the IASLC 2020 Lung Cancer Hot Topic: Liquid Biopsy Virtual Conference.
(Amgen) Oct 5, 2020 - Amgen today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 126 patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), who had failed a median of two prior lines of anti-cancer therapies (immunotherapy and/or...
(BMS) Oct 2, 2020 - Opdivo + Yervoy is the first new systemic therapy in over 15 years to be approved by the FDA in this setting. Approval is based on CheckMate -743 in which Opdivo + Yervoy demonstrated superior overall survival vs. standard of care chemotherapy. Approval marks third indication for Opdivo + Yervoy-based treatments in...
View all lung (includes nsclc, sclc, mesothelioma) cancer news

News Commentary

Editor Image
This result represents an important milestone, but we need to see the data to...
Editor Image
We can debate whether we're out far enough to call these patients cured, but...

Clinical Briefs

In a study reported at the European Society of Medical Oncology (ESMO) Virtual Congress 2020 ESMO Meeting, first-line cemiplimab monotherapy significantly improved overall survival (OS) and progression-free (PFS) vs platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) whose tumors express PD-L1 ≥50%. Despite a high crossover rate, the study provided a rationale for cemiplimab as a new treatment option for this patient population.

Featured Lung (includes NSCLC, SCLC, Mesothelioma) Cancer Tweets

David R. Gandara, MD
drgandara - Oct 03  Figuring out how to implement early detection-screening for the growing population of never-smokers who get lung ca… https://t.co/U3Ue0J7QbL

H. Jack West, MD
JackWestMD - Oct 02  T4) LUNGART trial directly tested role of post-op radiation for stage IIIA N2 resected NSCLC & showed no benefit w/… https://t.co/pPu0YBuwlD

Roy S. Herbst, MD
DrRoyHerbstYale - Sep 19  20 years of progress for EGFR inhibition in NSCLC! Lung Cancer Targeted Therapy now moves to the early/resectable… https://t.co/T2noPctSES